Open AccessRucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
Author(s) -
Wassim Abida,
Akash Patnaik,
David Campbell,
Jeremy Shapiro,
Alan H. Bryce,
Ray McDermott,
Brieuc Sautois,
Nicholas J. Vogelzang,
Richard Bambury,
Éric Voog,
Jingsong Zhang,
Josep María Piulats,
Charles J. Ryan,
Axel S. Merseburger,
Gedske Daugaard,
Axel Heidenreich,
Karim Fizazi,
Celestia S. Higano,
Laurence E. Krieger,
Cora N. Sternberg,
Simon P. Watkins,
Darrin Despain,
Andrew Simmons,
Andrea Loehr,
Melanie Dowson,
Tony Golsorkhi,
Simon Chowdhury
Publication year - 2020
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.20.01035
Subject(s) - medicine , prostate cancer , taxane , oncology , olaparib , cancer , parp inhibitor , breast cancer , poly adp ribose polymerase , gene , biochemistry , chemistry , polymerase
BRCA1 or BRCA2 ( BRCA ) alterations are common in men with metastatic castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors. We present results from patients with mCRPC associated with a BRCA alteration treated with rucaparib 600 mg twice daily in the phase II TRITON2 study.